Lambertville, NJ, United States of America

Joseph Barbosa

USPTO Granted Patents = 16 (Patent Applications = 6)

CIPO Patents = 2 (Patent Applications = 4)

EPO Patents = 5 (Patent Applications = 6)

Average Co-Inventor Count = 4.4

ph-index = 6

Forward Citations = 112(Granted Patents)

Location History:

Wilmington, DE (US) (2020)
Lambertville, NJ (US) (2005 - 2023)

Company Filing History:

9 out of 3,684

Bristol-myers Squibb Compnay

Lexicon Pharmaceuticals, Inc.

patents

Years Active: 2005-2025

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12415809 - Pyrrolotriazine compounds as tam inhibitors (2025-09-16),

2. 12187725 - Tricyclic urea compounds as JAK2 V617F inhibitors (2025-01-07),

3. 11780840 - Tricyclic urea compounds as JAK2 V617F inhibitors (2023-10-10),

4. 10723705 - Heterocyclic compounds and uses thereof (2020-07-28),

5. 9624238 - 4H-thieno[3,2-C]chromene-based inhibitors of Notum Pectinacetylesterase and methods of their use (2017-04-18),

6. 8772291 - Multicyclic compounds and methods of their use (2014-07-08),

7. 7981881 - Fused heterocyclic compounds and use thereof (2011-07-19),

8. 7601836 - Pyrido[2,3-D]pyrimidine inhibitors of phosphodiesterase (PDE) 7 (2009-10-13),

9. 7595317 - Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases (2009-09-29),

10. 7384937 - Fused heterocyclic compounds and use thereof (2008-06-10),

11. 7300949 - Thiazolopyrazoles and methods of their use (2007-11-27),

12. 7294624 - Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases (2007-11-13),

13. 7105667 - Fused heterocyclic compounds and use thereof (2006-09-12),

14. 7087614 - Pyrimidine inhibitors of phosphodiesterase (PDE) 7 (2006-08-08),

15. 7022849 - Quinazoline and pyrido[2,3-d]pyrimidine inhibitors of phosphodiesterase (PDE) 7 (2006-04-04),

Title: The Innovative Contributions of Joseph Barbosa

Introduction

Joseph Barbosa is a prominent inventor based in Lambertville, NJ (US), known for his significant contributions to the field of pharmaceuticals. With a remarkable portfolio of 16 patents, Barbosa has made strides in developing compounds that target critical health issues, particularly in cancer treatment.

Latest Patents

Among his latest innovations are the Pyrrolotriazine compounds as tam inhibitors, which relate to compounds of Formula I. Additionally, he has developed tricyclic urea compounds as JAK2 V617F inhibitors. These compounds are designed to modulate the activity of the V617F variant of JAK2, offering potential therapeutic benefits for various diseases, including cancer.

Career Highlights

Throughout his career, Barbosa has worked with notable companies such as Bristol-Myers Squibb Company and Incyte Corporation. His experience in these leading pharmaceutical firms has allowed him to contribute to groundbreaking research and development in the industry.

Collaborations

Barbosa has collaborated with esteemed colleagues, including William John Pitts and Junqing Guo, enhancing the scope and impact of his work in the field.

Conclusion

Joseph Barbosa's innovative spirit and dedication to advancing medical science through his patents and collaborations have established him as a key figure in pharmaceutical research. His work continues to inspire future innovations in the industry.

This text is generated by artificial intelligence and may not be accurate.